Literature DB >> 17295771

Long-term outcome of chronic hepatitis B based on histological grade and stage.

Byung Kyu Park1, Young Nyun Park, Sang Hoon Ahn, Kwan Sik Lee, Chae Yoon Chon, Young Myoung Moon, Chanil Park, Kwang-Hyub Han.   

Abstract

BACKGROUND AND AIM: This study evaluated the long-term outcome and prognostic factors of chronic hepatitis B, based on histological grade and stage.
METHODS: A total of 188 patients with chronic hepatitis B were followed for a mean 119.8 months. Ultrasonography and clinical assessment were performed regularly. In addition, liver biopsy specimens were re-evaluated based on histological grade and stage.
RESULTS: During follow-up, cirrhosis developed in 62 patients, decompensation in 20 patients, and hepatocellular carcinoma (HCC) in 21 patients. The serum alanine aminotransferase (ALT) level at the time of liver biopsy was significantly correlated with the grades of lobular and porto-periportal activity. The development of cirrhosis correlated well with the grade of porto-periportal activity and stage of fibrosis. The probabilities of developing cirrhosis, decompensation and HCC were significantly higher in patients whose ALT levels were persistently elevated without flares or flared-up without normalization than in patients whose ALT levels flared-up then normalized or were normally sustained. By multivariate analysis, age and biochemical profile during follow-up were independent prognostic factors for chronic hepatitis B.
CONCLUSIONS: The results demonstrate that histological grade and stage, and biochemical profile during follow-up in patients with chronic hepatitis B are important prognostic factors. Therefore, effective control of hepatitis activity might improve the long-term outcome of chronic hepatitis B patients.

Entities:  

Mesh:

Year:  2007        PMID: 17295771     DOI: 10.1111/j.1440-1746.2007.04857.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  32 in total

1.  Towards a rational treatment strategy for chronic hepatitis B.

Authors:  Yun-Fan Liaw
Journal:  Hepatol Int       Date:  2007-06-06       Impact factor: 6.047

2.  Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma.

Authors:  Gengming Huang; Joseph D Krocker; Jason L Kirk; Shehzad N Merwat; Hyunsu Ju; Roger D Soloway; Lucas R Wieck; Albert Li; Anthony O Okorodudu; John R Petersen; Nihal E Abdulla; Andrea Duchini; Luca Cicalese; Cristiana Rastellini; Peter C Hu; Jianli Dong
Journal:  Clin Chem Lab Med       Date:  2014-06       Impact factor: 3.694

Review 3.  Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates.

Authors:  Ahmad Najib Azmi; Soek-Siam Tan; Rosmawati Mohamed
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

4.  Validation of Shear Wave Elastography Cutoff Values on the Supersonic Aixplorer for Practical Clinical Use in Liver Fibrosis Staging.

Authors:  Manish Dhyani; Joseph R Grajo; Atul K Bhan; Kathleen Corey; Raymond Chung; Anthony E Samir
Journal:  Ultrasound Med Biol       Date:  2017-03-22       Impact factor: 2.998

Review 5.  Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis.

Authors:  Koichi Honda; Masataka Seike; Kazunari Murakami
Journal:  World J Hepatol       Date:  2015-10-08

6.  Chronic hepatitis B: correlation of abnormal features on T2-weighted imaging and dynamic contrast-enhanced imaging with hepatic histopathology.

Authors:  Jian Shu; Jian Nong Zhao; Fu Gang Han; Guang Cai Tang; Xin Chen
Journal:  Radiol Med       Date:  2017-07-10       Impact factor: 3.469

7.  Effects of variant rs346473 in ARHGAP24 gene on disease progression of HBV infection in Han Chinese population.

Authors:  Lifeng Liu; Jinjian Yao; Jin Li; Jinliang Zhang; Jinling Yu; Xiaorui Jiang; Shuzhen Sun; Qing Liu; Ying Chang; Yongwen He; Jusheng Lin
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

8.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

Authors:  Yun-Fan Liaw; Nancy Leung; Jia-Horng Kao; Teerha Piratvisuth; Edward Gane; Kwang-Hyub Han; Richard Guan; George K K Lau; Stephen Locarnini
Journal:  Hepatol Int       Date:  2008-05-10       Impact factor: 6.047

9.  Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.

Authors:  Sang Hoon Ahn; Henry L Y Chan; Pei-Jer Chen; Jun Cheng; Mahesh K Goenka; Jinlin Hou; Seng Gee Lim; Masao Omata; Teerha Piratvisuth; Qing Xie; Hyung Joon Yim; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2010-02-20       Impact factor: 6.047

10.  Management of chronic hepatitis B: consensus guidelines.

Authors:  Morris Sherman; Stephen Shafran; Kelly Burak; Karen Doucette; Winnie Wong; Nigel Girgrah; Eric Yoshida; Eberhard Renner; Philip Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.